Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

被引：0
|
作者：
Florian R Fritzsche
Wilko Weichert
Annika Röske
Volker Gekeler
Thomas Beckers
Carsten Stephan
Klaus Jung
Katharina Scholman
Carsten Denkert
Manfred Dietel
Glen Kristiansen
机构：
[1] Charité – Universitätsmedizin,Institute of Pathology
[2] Charité – Universitätsmedizin,Department of Urology
[3] Nycomed GmbH,Institute of Surgical Pathology
[4] Oncotest GmbH,undefined
[5] Berlin Institute for Urologic Research,undefined
[6] UniversitätsSpital Zürich,undefined
来源：
BMC Cancer | / 8卷
关键词：
Renal Cell Carcinoma; HDAC Inhibitor; Renal Cell Cancer; SAHA; Tumour Entity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
    Fritzsche, Florian R.
    Weichert, Wilko
    Roeske, Annika
    Gekeler, Volker
    Beckers, Thomas
    Stephan, Carsten
    Jung, Klaus
    Scholman, Katharina
    Denkert, Carsten
    Dietel, Manfred
    Kristiansen, Glen
    [J]. BMC CANCER, 2008, 8 (1)
  • [2] Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
    Adams, Heiner
    Fritzsche, Florian R.
    Dirnhofer, Stephan
    Kristiansen, Glen
    Tzankov, Alexandar
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (06) : 577 - 584
  • [3] Histone deacetylases 3 (HDAC3) is highly expressed in cervical cancer and inhibited by siRNA
    Zhang, Li
    Yuan, Chuantao
    Wang, Yunfei
    Zhao, Shuping
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (03): : 3600 - 3605
  • [4] Targeting class I histone deacetylases in cancer therapy
    Delcuve, Genevieve P.
    Khan, Dilshad H.
    Davie, James R.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (01) : 29 - 41
  • [5] Class I histone deacetylases (HDAC1-3) are histone lysine delactylases
    Moreno-Yruela, Carlos
    Zhang, Di
    Wei, Wei
    Baek, Michael
    Liu, Wenchao
    Gao, Jinjun
    Dankova, Daniela
    Nielsen, Alexander L.
    Bolding, Julie E.
    Yang, Lu
    Jameson, Samuel T.
    Wong, Jiemin
    Olsen, Christian A.
    Zhao, Yingming
    [J]. SCIENCE ADVANCES, 2022, 8 (03):
  • [6] Expression profile of class I histone deacetylases in human cancer tissues
    Nakagawa, Masamune
    Oda, Yoshinao
    Eguchi, Takashi
    Aishima, Shin-Ichi
    Yao, Takashi
    Hosoi, Fumihito
    Basakv, Yuji
    Ono, Mayumi
    Kuwano, Michihiko
    Tanaka, Masao
    Tsuneyoshi, Masazumi
    [J]. ONCOLOGY REPORTS, 2007, 18 (04) : 769 - 774
  • [7] Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms
    Pinkerneil, Maria
    Hoffmann, Michele J.
    Deenen, Rene
    Koehrer, Karl
    Arent, Tanja
    Schulz, Wolfgang A.
    Niegisch, Guenter
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (02) : 299 - 312
  • [8] Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases
    Hildmann, Christian
    Wegener, Dennis
    Riester, Daniel
    Hempel, Rene
    Schober, Andreas
    Merana, Joachim
    Giurato, Laura
    Guccione, Salvatore
    Nielsen, Tine Kragh
    Ficner, Ralf
    Schwienhorst, Andreas
    [J]. JOURNAL OF BIOTECHNOLOGY, 2006, 124 (01) : 258 - 270
  • [9] Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer
    Poyet, Cedric
    Jentsch, Bastian
    Hermanns, Thomas
    Schweckendiek, Daniel
    Seifert, Hans-Helge
    Schmidtpeter, Martin
    Sulser, Tullio
    Moch, Holger
    Wild, Peter J.
    Kristiansen, Glen
    [J]. BMC CLINICAL PATHOLOGY, 2014, 14
  • [10] Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer
    Shankar, Eswar
    Pandey, Mitali
    Verma, Shiv
    Abbas, Ata
    Candamo, Mario
    Kanwal, Rajnee
    Shukla, Sanjeev
    MacLennan, Gregory T.
    Gupta, Sanjay
    [J]. MOLECULAR CARCINOGENESIS, 2020, 59 (08) : 955 - 966
12345